Neuroleptic Malignant Syndrome Secondary to Quetiapine in Critical Care: A Case Report. Issue 11 (September 2020)

• Record Type: Journal Article
• Authors: Nestor, C.; O'Brien, D.; Dwyer, R.
• Is Part Of: A & A practice. Volume 14:Issue 11(2020)
• Publication Date: 2020-09
• Subjects: Analgesia -- Periodicals; Analgesia -- Case studies -- Periodicals; Anesthesiology -- Periodicals; Anesthesiology -- Case studies -- Periodicals; 617.9605
• DOI: 10.1213/XAA.0000000000001318
• Languages: English
• ISSNs: 2575-3126

Abstract

Abstract : Quetiapine, an atypical antipsychotic, is widely used to treat delirium in intensive care units (ICUs). Studies demonstrate its efficacy and favorable safety profile. We report a case of an elderly patient who developed clinical and biochemical evidence of neuroleptic malignant syndrome (NMS) 5 days after quetiapine was commenced. Signs of NMS resolved after discontinuation of quetiapine and administration of dantrolene. Quetiapine-induced NMS has occurred with long-term use in the elderly in the outpatient setting. However, NMS has not previously been reported after treatment of ICU delirium. NMS is an important complication to consider before prescribing quetiapine in the ICU.